252 related articles for article (PubMed ID: 12007528)
1. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
Arch JR
Eur J Pharmacol; 2002 Apr; 440(2-3):99-107. PubMed ID: 12007528
[TBL] [Abstract][Full Text] [Related]
2. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer C; Gautier JF; Danforth E
Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
[TBL] [Abstract][Full Text] [Related]
3. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
Arch JR; Ainsworth AT; Ellis RD; Piercy V; Thody VE; Thurlby PL; Wilson C; Wilson S; Young P
Int J Obes; 1984; 8 Suppl 1():1-11. PubMed ID: 6152555
[TBL] [Abstract][Full Text] [Related]
4. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
Arch JR
Naunyn Schmiedebergs Arch Pharmacol; 2008 Aug; 378(2):225-40. PubMed ID: 18612674
[TBL] [Abstract][Full Text] [Related]
5. The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice.
Fu L; Isobe K; Zeng Q; Suzukawa K; Takekoshi K; Kawakami Y
Eur J Pharmacol; 2008 Apr; 584(1):202-6. PubMed ID: 18304529
[TBL] [Abstract][Full Text] [Related]
6. Contrasts between the effects of zinc-α2-glycoprotein, a putative β3/2-adrenoceptor agonist and the β3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice.
Wargent ET; O'Dowd JF; Zaibi MS; Gao D; Bing C; Trayhurn P; Cawthorne MA; Arch JR; Stocker CJ
J Endocrinol; 2013 Feb; 216(2):157-68. PubMed ID: 23151357
[TBL] [Abstract][Full Text] [Related]
7. Anti-obesity and metabolic efficacy of the β3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C.
Xiao C; Goldgof M; Gavrilova O; Reitman ML
Obesity (Silver Spring); 2015 Jul; 23(7):1450-9. PubMed ID: 26053335
[TBL] [Abstract][Full Text] [Related]
8. The effects and selectivity of beta-adrenoceptor agonists in rat myometrium and urinary bladder.
Clouse AK; Riedel E; Hieble JP; Westfall TD
Eur J Pharmacol; 2007 Nov; 573(1-3):184-9. PubMed ID: 17632099
[TBL] [Abstract][Full Text] [Related]
9. CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats.
de Souza CJ; Hirshman MF; Horton ES
Diabetes; 1997 Aug; 46(8):1257-63. PubMed ID: 9231648
[TBL] [Abstract][Full Text] [Related]
10. The beta3-adrenergic agonist CL316,243 inhibits insulin signaling but not glucose uptake in primary human adipocytes.
Jost MM; Jost P; Klein J; Klein HH
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):418-22. PubMed ID: 16151974
[TBL] [Abstract][Full Text] [Related]
11. Apparent lack of beta 3-adrenoceptors and of insulin regulation of glucose transport in brown adipose tissue of guinea pigs.
Himms-Hagen J; Triandafillou J; Begin-Heick N; Ghorbani M; Kates AL
Am J Physiol; 1995 Jan; 268(1 Pt 2):R98-104. PubMed ID: 7840345
[TBL] [Abstract][Full Text] [Related]
12. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
de Souza CJ; Burkey BF
Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
[TBL] [Abstract][Full Text] [Related]
13. Further evidence for differences between cardiac atypical beta-adrenoceptors and brown adipose tissue beta3-adrenoceptors in the pithed rat.
Malinowska B; Schlicker E
Br J Pharmacol; 1997 Dec; 122(7):1307-14. PubMed ID: 9421276
[TBL] [Abstract][Full Text] [Related]
14. [Beta 3 adrenergic receptor: physiologic role and potential therapeutic applications].
Balligand JL
Bull Mem Acad R Med Belg; 2000; 155(7-9):311-7; discussion 317-9. PubMed ID: 11388023
[TBL] [Abstract][Full Text] [Related]
15. Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor.
Hutchinson DS; Chernogubova E; Sato M; Summers RJ; Bengtsson T
Naunyn Schmiedebergs Arch Pharmacol; 2006 May; 373(2):158-68. PubMed ID: 16601951
[TBL] [Abstract][Full Text] [Related]
16. Temperature matters with rodent metabolic studies.
Ravussin Y
Obesity (Silver Spring); 2015 Jul; 23(7):1330. PubMed ID: 26054845
[No Abstract] [Full Text] [Related]
17. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
Weyer C; Tataranni PA; Snitker S; Danforth E; Ravussin E
Diabetes; 1998 Oct; 47(10):1555-61. PubMed ID: 9753292
[TBL] [Abstract][Full Text] [Related]
18. CNS β
Richard JE; López-Ferreras L; Chanclón B; Eerola K; Micallef P; Skibicka KP; Wernstedt Asterholm I
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E344-E358. PubMed ID: 28588096
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist.
Margareto J; Larrarte E; Marti A; Martinez JA
Biochem Pharmacol; 2001 Jun; 61(12):1471-8. PubMed ID: 11377376
[TBL] [Abstract][Full Text] [Related]
20. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation.
Barbatelli G; Murano I; Madsen L; Hao Q; Jimenez M; Kristiansen K; Giacobino JP; De Matteis R; Cinti S
Am J Physiol Endocrinol Metab; 2010 Jun; 298(6):E1244-53. PubMed ID: 20354155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
